Patents by Inventor Charles C. Reed

Charles C. Reed has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220031814
    Abstract: Described are nicotine-degrading enzyme variants that exhibit increased nicotine-degrading activity and/or decreased immunogenicity relative to the wild-type NicA2 enzyme, compositions comprising the variants, and methods using them.
    Type: Application
    Filed: July 2, 2019
    Publication date: February 3, 2022
    Applicant: ANTIDOTE THERAPEUTICS, INC.
    Inventors: Matthew W. KALNIK, Thomas THISTED, Charles C. REED
  • Publication number: 20200239906
    Abstract: This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing vectors for one or more immunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. These vector may be provided to treat a variety of disorders, e.g., neoplastic disorders, through direct injection or through in vitro engineered cells, such as dendritic cells.
    Type: Application
    Filed: January 9, 2020
    Publication date: July 30, 2020
    Inventors: Jeremiah F. Roeth, Charles C. Reed, Brandon Cuthbertson, Sunil Chada, William E. Fogler
  • Publication number: 20200224176
    Abstract: Described are nicotine-degrading enzyme variants that exhibit increased nicotine-degrading activity and/or decreased immunogenicity relative to the wild-type NicA2 and NOX enzymes, compositions comprising the variants, and methods using them.
    Type: Application
    Filed: February 2, 2018
    Publication date: July 16, 2020
    Applicants: ANTIDOTE THERAPEUTICS, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Matthew W. KALNIK, Thomas THISTED, Everett STONE, Charles C. REED, Max RODNICK-SMITH
  • Patent number: 10584351
    Abstract: This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing vectors for one or more immuunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. These vector may be provided to treat a variety of disorders, e.g., neoplastic disorders, through direct injection or through in vitro engineered cells, such as dendritic cells.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: March 10, 2020
    Assignee: Intrexon Corporation
    Inventors: Jeremiah F. Roeth, Charles C. Reed, Brandon Cuthbertson, Sunil Chada, William E. Fogler
  • Publication number: 20180344876
    Abstract: This invention relates to the field of therapeutics. Disclosed are methods of generating conditionally expressing erythropoietin under the control of an ecdysone receptor-based gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. The methods of the invention cause an in vivo increase in the expression of erythropoietin and an increase in the hematocrit or volume percentage of red blood cells in blood after administration of the ligand.
    Type: Application
    Filed: May 31, 2018
    Publication date: December 6, 2018
    Applicant: Intrexon Corporation
    Inventors: Jeremiah F. ROETH, Charles C. REED, Brandon CUTHERTSON, Sunil CHADA, William E. FOGLER, Fayaz KHAZI
  • Publication number: 20180002719
    Abstract: This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing vectors for one or more immuunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. These vector may be provided to treat a variety of disorders, e.g., neoplastic disorders, through direct injection or through in vitro engineered cells, such as dendritic cells.
    Type: Application
    Filed: July 13, 2017
    Publication date: January 4, 2018
    Applicant: Intrexon Corporation
    Inventors: Jeremiah F. ROETH, Charles C. Reed, Brandon Cuthbertson, Sunil Chada, William E. Fogler
  • Publication number: 20170291934
    Abstract: The present invention relates to modified forms of IL-12. These modified forms of IL-12 may be engineered to have a shortened in vivo half-life compared and/or enhanced localization of biological effects compared to that of corresponding non-modified form of IL-12. Short half-life and membrane bound forms of IL-12 may provide greater therapeutic control for in vivo therapeutic delivery, in particular when used in combination with ligand inducible delivery of IL-12. Modified forms of IL-12 engineered to have shortened in vivo half-life and/or enhanced localization of biological effects include heterodimeric p35/p40, single chain and membrane bound forms of IL-12 wherein a naturally occurring IL-12 amino acid sequence is genetically modified to enhance susceptibility of the IL-12 molecule to in vivo proteolytic degradation.
    Type: Application
    Filed: September 21, 2015
    Publication date: October 12, 2017
    Inventors: CHARLES C. REED, GREGORY IAN FROST, JOAN MAZZARELLI SOPCZYNSKI, CHI ZHANG
  • Publication number: 20160317678
    Abstract: This invention relates to the field of therapeutics. Disclosed are methods of generating conditionally expressing erythropoietin under the control of an ecdysone receptor-based gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. The methods of the invention cause an in vivo increase in the expression of erythropoietin and an increase in the hematocrit or volume percentage of red blood cells in blood after administration of the ligand.
    Type: Application
    Filed: May 11, 2016
    Publication date: November 3, 2016
    Inventors: Jeremiah F. ROETH, Charles C. Reed, Brandon Cuthbertson, Sunil Chada, William E. Fogler, Fayaz Khazi
  • Patent number: 9402919
    Abstract: This invention relates to the field of therapeutics. Disclosed are methods of conditionally expressing erythropoietin under the control of an ecdysone receptor-based gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. The methods of the invention cause an in vivo increase in the expression of erythropoietin and an increase in the hematocrit or volume percentage of red blood cells in blood after administration of the ligand.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: August 2, 2016
    Assignee: Intrexon Corporation
    Inventors: Jeremiah F. Roeth, Charles C. Reed, Brandon Cuthbertson, Sunil Chada, William E. Fogler, Fayaz Khazi
  • Publication number: 20160208285
    Abstract: This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing vectors for one or more immunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. These vector may be provided to treat a variety of disorders, e.g., neoplastic disorders, through direct injection or through in vitro engineered cells, such as dendritic cells.
    Type: Application
    Filed: December 29, 2015
    Publication date: July 21, 2016
    Inventors: Jeremiah F. Roeth, Charles C. Reed, Brandon Cuthbertson, Sunil Chada, William E. Fogler
  • Publication number: 20140308247
    Abstract: This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing one or more proteins under the control of a gene expression modulation, system in the presence of activating ligand and uses for therapeutic purposes in animals. The vector may be provided to treat or prevent disease.
    Type: Application
    Filed: March 2, 2012
    Publication date: October 16, 2014
    Applicant: Intrexon Corporation
    Inventors: Jeremiah F. Roeth, Brandon Cuthbertson, Charles C. Reed, Sunil Chada, William E. Fogler, Fayas Khazi
  • Publication number: 20130195800
    Abstract: This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing vectors for one or more immunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. These vector may be provided to treat a variety of disorders, e.g., neoplastic disorders, through direct injection or through in vitro engineered cells, such as dendritic cells.
    Type: Application
    Filed: March 23, 2011
    Publication date: August 1, 2013
    Applicant: Intrexon Corporation
    Inventors: Jeremiah F. Roeth, Charles C. Reed, Brandon Cuthbertson, Sunil Chada, William E. Fogler
  • Patent number: 8431363
    Abstract: The invention relates to mammalian PAI-I ligands and modulators. In particular, the invention relates to polypeptides, polypeptide compositions and polynucleotides that encode polypeptides that are ligands and/or modulators of PAI-I. The invention also relates to polyligands that are homopolyligands or heteropolyligands that modulate PAI-I activity. The invention also relates to ligands and polyligands localized to a region of a cell. The invention also relates to localization tethers and promoter sequences that can be used to provide spatial control of the PAI-I ligands and polyligands. The invention also relates to inducible gene switches that can be used to provide temporal control of the PAI-I ligands and polyligands. The invention also relates to methods of treating or preventing atherosclerosis. The invention also relates to methods of treating or preventing fibrosis.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: April 30, 2013
    Assignee: Intrexon Corporation
    Inventors: Thomas D. Reed, Richard E. Peterson, Charles C. Reed, Joan Mazzarelli Sopczynski, Bethany L. Merenick, Jonathan Carson, Catherine L. Bair, Elena Tasheva
  • Publication number: 20110055940
    Abstract: The invention relates to mammalian PAI-I ligands and modulators. In particular, the invention relates to polypeptides, polypeptide compositions and polynucleotides that encode polypeptides that are ligands and/or modulators of PAI-I. The invention also relates to polyligands that are homopolyligands or heteropolyligands that modulate PAI-I activity. The invention also relates to ligands and polyligands localized to a region of a cell. The invention also relates to localization tethers and promoter sequences that can be used to provide spatial control of the PAI-I ligands and polyligands. The invention also relates to inducible gene switches that can be used to provide temporal control of the PAI-I ligands and polyligands. The invention also relates to methods of treating or preventing atherosclerosis. The invention also relates to methods of treating or preventing fibrosis.
    Type: Application
    Filed: January 9, 2009
    Publication date: March 3, 2011
    Applicant: Intrexon Corporation
    Inventors: Thomas D. Reed, Richard E. Peterson, Charles C. Reed, Joan Mazzarelli Sopczynski, Bethany L. Merenick, Jonathan Carson, Catherine L. Bair, Elena Tasheva
  • Patent number: 4704203
    Abstract: A novel cardiotomy reservoir apparatus and method for use in an extracorporeal blood circuit which provides for the effective defoaming of blood that has been aspirated from a patient during surgery. The apparatus includes an outer receptacle, which is preferably generally cylindrical in shape, the receptacle having at least one inlet formed in the top thereof, an outlet formed in the bottom thereof, and a vent port. The receptacle contains a defoaming means which substantially occupies the entire interior volume of the receptacle, and which has an increasing density in the direction of blood flow through the receptacle. In addition, the cardiotomy reservoir of the present invention may be used with an external blood filter and the outlet of the reservoir receptacle has a valve formed therein to facilitate rapid and safe replacement of the external filter in the event that it becomes occluded.
    Type: Grant
    Filed: June 9, 1986
    Date of Patent: November 3, 1987
    Inventor: Charles C. Reed
  • Patent number: 4637917
    Abstract: A bubble oxygenator for oxygenating blood in an extracorporeal circuit. The oxygenator is formed from three concentric shells which define an oxygenating chamber, a defoaming chamber and an arterial reservoir. The arterial reservoir includes a view chamber which permits visual inspection of the level of blood held in the arterial reservoir. The outer shell which forms the arterial reservoir is rotatable with respect to the remainder of the apparatus so that the view chamber can be easily positioned for observation.
    Type: Grant
    Filed: October 14, 1983
    Date of Patent: January 20, 1987
    Inventors: Charles C. Reed, Denton A. Cooley, Terry N. Crane, Edward A. Swanson, Rolf A. Oscarsson, Vern L. Liebmann, Dan L. Cox
  • Patent number: 4631050
    Abstract: An autotransfusion system for salvaging, washing, and concentrating blood and returning the blood to a patient during surgery. The system comprises both a filtration unit and an ultrafiltration unit. The ultrafiltration unit is configured so as to communicate with the filtration unit, and both the filtration unit and the ultrafiltration unit are provided with a suitable conduit for conveying blood back to a patient. The ultrafiltration unit is divided into two chambers by a semipermeable membrane, the membrane being selected so as to permit fluid to pass therethrough, while preventing the passage of blood cells and other formed elements.A mixture of healthy blood cells, fluid, and particulate debris is salvaged from an operative field of a patient. The blood mixture is filtered in the filtration unit and can then be immediately returned to the patient, if needed.
    Type: Grant
    Filed: September 24, 1985
    Date of Patent: December 23, 1986
    Inventors: Charles C. Reed, Denton A. Cooley
  • Patent number: 4493692
    Abstract: Novel methods and apparatus are provided for regulating the concentrations of oxygen and carbon dioxide in blood during extracorporeal cardiopulmonary bypass. According to the invention, probes capable of measuring the partial pressures of oxygen and carbon dioxide in blood are provided in the venous and arterial lines, both probes measuring the blood gas levels at the ambient temperature of the blood in the extracorporeal blood circuit. These concentrations are monitored on a real-time basis by a processor unit which compares the values reported by the arterial probe with selected values chosen by the perfusionist. The processor unit then preferably controls the gas flow to the oxygenator portion of the perfusion system so that the treated blood maintains the chosen concentrations of oxygen and carbon dioxide. In other embodiments, the probes are adapted to measure other perfusion variables, including temperature, hematocrit, blood flow rate, and pH, thus allowing further automation by the processor unit.
    Type: Grant
    Filed: September 29, 1982
    Date of Patent: January 15, 1985
    Inventor: Charles C. Reed
  • Patent number: 4489446
    Abstract: A heart valve prosthesis incorporating a dynamic stiffener element is disclosed. The prosthesis is adapted for securement to the annulus of an atrioventricular valve and has the characteristic of allowing normal movement of the annulus during the cardiac cycle while providing mechanical support to the valve annulus so as to maintain the valve leaflets in proper physiological alignment. The stiffener element has a plurality of reciprocating members allowing it to be modifiable in shape so as to be capable of assuming the optimum shape for a particular heart valve.
    Type: Grant
    Filed: July 14, 1982
    Date of Patent: December 25, 1984
    Inventor: Charles C. Reed
  • Patent number: 4422939
    Abstract: A blood and perfusate filter apparatus having a pair of molded housing members that are substantially identical in their configuration. The upper housing member having a pyramidal-shaped reservoir formed in the upper surface thereof which acts as a secondary distribution reservoir, and the lower housing member having a pyramidal-shaped reservoir formed in the lower surface thereof which acts as a secondary collection reservoir. Interchangeable tubing couplings are press-fit bonded to inlet/outlet ports located in the secondary reservoirs. A filter element, mounted in a resinous band, is bonded between the housing members so as to filter blood or perfusate as it passes through the filter. The filter element also forms primary distribution and collection reservoirs with respect to the upper and lower housing members. Different types of filter configurations, such as flat or pleated, can be mounted in a resinous band and used as the filter media.
    Type: Grant
    Filed: April 8, 1982
    Date of Patent: December 27, 1983
    Assignee: Texas Medical Products, Inc.
    Inventors: Russell G. Sharp, William R. Wilkinson, Charles C. Reed, Denton A. Cooley